Author: Kirkimbaeva Sandugash
Translator: Issabayeva Madina
Copy editor: Kigbaeva Kamila
On June 3, 2020 in Seoul, the Ministry of Food and Drug Safety of South Korea signed a permit for the purchase of an antiviral drug "Remidesivir" for the treatment of coronavirus infection.
The drug was previously approved in the United States for treatment of COVID-19 (May 1, 2020). Prior to this, "Remidesivir" was used in the treatment of Ebola, but it had no effect. It was later successfully used in the treatment of SARS and MERS infections. An international team of scientists is currently conducting clinical trials on patients with severe COVID-19.
Antiviral drug "Remidesivir" is produced by the American biopharmaceutical company Gilead Sciences. The Ministry of Food and Drug Safety has approved "the necessity and use of the drug in other countries".
In the near future a contract will be signed with «Gilead Sciences Korea» about deliveries of "Remidesivira" on a special import system. This means that, in crisis cases, previously unauthorized medicines required for the treatment of epidemics or for public health will be allowed. The drug has not yet arrived in the country.
In South Korea, about 5% of all COVID-19 patients are in critical condition. KCDC (Korean Centers for Disease Control and Prevention) recommend the use of "Remidesivir", even if the drug’s clinical trials are incomplete.
To date, 11,590 cases of coronavirus infection have been reported in South Korea, more than 90 per cent have recovered and 273 people have died.
Source: https://ria.ru/
